triazolam has been researched along with Dissociation in 1 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Weingartner, HJ | 1 |
| Sirocco, K | 1 |
| Rawlings, R | 1 |
| Joyce, E | 1 |
| Hommer, D | 1 |
1 trial available for triazolam and Dissociation
| Article | Year |
|---|---|
Dissociations in the expression of the sedative effects of triazolam.
Topics: Administration, Oral; Animals; Cross-Over Studies; Dissociative Disorders; Dose-Response Relationshi | 1995 |